Hematology Biobank: In Vitro Study of Blood Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2030-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a biorepository of blood specimens from subjects with different Hematological disorders.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Blood Cell Disorders Tissue Bank

NCT00902447

Human Blood Cell Disorders Lymphoid, Myeloid and Erythroid Proliferative Disease

RECRUITING

Screening for Subjects to Participate in Studies of Blood Disorders

NCT00695123

Bone Marrow Transplant Sickle Cell Disease G-CSF

COMPLETED

Screening for Hematology Branch Protocols

NCT00001620

Hematologic Disease and Disorders Donors Healthy Volunteer

ENROLLING_BY_INVITATION

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

NCT07227155

Aplastic Anemias Hemoglobinopathies Bone Marrow Failure

NOT_YET_RECRUITING

Evaluation, Treatment, and Training for Patients With Blood Disorders

NCT00001397

Hematologic Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There has been a marked increase in our knowledge of Blood Disorders in the last decade. Much of this knowledge comes from examining blood specimens from patients and subjecting these samples to red cell, plasma, serum or DNA analyses. The study team proposes to set up a Hematology biobank, which will include patient histories, their medical progress and a linked but de-identified bank of blood samples. This will enable researchers to have a large database, which can be used to learn more about these diseases.

The Hematology biobank will use whole blood, red blood cells, plasma, serum and/or DNA. Whole blood specimens, which by definition include the white cells that contain DNA, will be collected and stored in the biobank repository at the Institute for Clinical and Translational Research (ICTR) for future studies.

Blood samples will be obtained from two sources:

1. Leftover/discarded whole blood samples that were obtained for standard of care.
2. Blood samples consisting of 1-5 tubes (3-20 ml of whole blood) from patients with written consent. When possible, these samples will be obtained during routine blood draws performed for a typical visit. It may be necessary to ask patients to specifically donate blood for the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematological Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Above 12 years of age and referred to the Hematology Division at Montefiore-Einstein
* Under the care of a Montefiore-Einstein hematologist for a hematologic disorder

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No